Tissue microarray (TMA) technology has transformed colorectal cancer research by enabling simultaneous analysis of hundreds of tissue samples under uniform experimental conditions. In this approach, ...
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results